Although their exact roles in MPN are still being defined, ASXL1 mutations are commonly found in CALR-mutant MPN patients and TET2 mutations are more frequent in JAK2 V617F-mutated MPN patients. Here, JAK2 is linked to myeloproliferative neoplasm.